Tuberculosis screening prior to anti‐tumor necrosis factor therapy among patients with immune‐mediated inflammatory diseases in Japan: a longitudinal study using a large‐scale health insurance claims database
- 26 October 2017
- journal article
- research article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (11) , 1674-1683
Abstract
Aim: Tuberculosis screening is recommended for patients with immune‐mediated inflammatory diseases (IMIDs) prior to anti‐tumor necrosis factor (TNF) therapy. However, adherence to the recommended practice is unknown in the current clinical setting in Japan.Methods: We used a large‐scale health insurance claims database in Japan to conduct a longitudinal observational study. Of more than two million beneficiaries in the database between 2013 and 2014, we enrolled those with IMIDs aged 15–69 years who had initiated anti‐TNF therapy. We defined tuberculosis screening primarily as tuberculin skin test and/or interferon‐gamma release assay (TST/IGRA) within 2 months before commencing anti‐TNF therapy. We analyzed the proportions of the patients who had undergone tuberculosis screening and the associations with primary disease, type of anti‐TNF agent, methotrexate prescription prior to anti‐TNF therapy, and treatment for latent tuberculosis infection (LTBI).Results: Of 385 patients presumed to have initiated anti‐TNF therapy, 252 (66%) had undergone tuberculosis screening by TST/IGRA (22% TST, 56% IGRA, and 12% both TST and IGRA), and 231 (60%) had undergone TST/IGRA and radiography. Patients with psoriasis tended to be more likely to undergo tuberculosis screening than those with other diseases; however, this association was not statistically significant. Treatment for LTBI was provided to 43 (11%) patients; 123 (32%) received neither TST/IGRA nor LTBI treatment.Conclusions: Tuberculosis screening was often not performed prior to anti‐TNF therapy despite the guidelines’ recommendations; thus, patients could be put at unnecessary risk of reactivation of tuberculosis.Keywords
Funding Information
- Ministry of Health, Labour and Welfare
- Japan Science and Technology Agency
This publication has 30 references indexed in Scilit:
- Biological agents and respiratory infections: Causative mechanisms and practice managementRespiratory Investigation, 2015
- The ‘either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatmentThe International Journal of Tuberculosis and Lung Disease, 2014
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid ArthritisPLOS ONE, 2012
- The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementEuropean Respiratory Journal, 2010
- Tumor necrosis factor antagonists in the therapy of psoriasisClinics in Dermatology, 2008
- Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's diseaseCochrane Database of Systematic Reviews, 2008
- Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- Infections in patients with rheumatoid arthritis treated with biologic agentsArthritis & Rheumatism, 2005
- Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor InhibitorClinical Infectious Diseases, 2004
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001